2
Views
1
CrossRef citations to date
0
Altmetric
Review

Recombinant adeno-associated virus vectors for somatic gene therapy in dermatology

&
Pages 167-177 | Published online: 10 Jan 2014

References

  • Khavari PA, Rollman O, Vahlquist A. Cutaneous gene transfer for skin and systemic diseases. J. Intern. Med.252(1), 1–10 (2002).
  • Flotte TR, Berns KI (Ed.). Adeno-associated Virus Vectors for Gene Therapy (1st Edition). Elsevier Science Ltd, GA, USA (2005).
  • Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther.14(3), 316–327 (2006).
  • Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr. Gene Ther.5(3), 285–297 (2005).
  • Gao G, Vandenberghe LH, Alvira MR et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol.78(12), 6381–6388 (2004).
  • Wu Z, Asokan A, Grieger JC et al. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol.80(22), 11393–11397 (2006).
  • Mori S, Wang L, Takeuchi T, Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology330(2), 375–383 (2004).
  • Chiorini JA, Wiener SM, Yang L et al. The roles of AAV Rep proteins in gene expression and targeted integration. Curr. Top. Microbiol. Immunol.218, 25–33 (1996).
  • Muzyczka N, Warrington KH Jr. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum. Gene Ther.16(4), 408–416 (2005).
  • Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene Ther.12(11), 873–880 (2005).
  • Sanlioglu S, Monick MM, Luleci G, Hunninghake GW, Engelhardt JF. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr. Gene Ther.1(2), 137–147 (2001).
  • Bartlett JS, Wilcher R, Samulski RJ. Infectious pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol.74(6), 2777–2785 (2000).
  • Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol.75(4), 1824–1833 (2001).
  • Zhao W, Zhong L, Wu J et al. Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. Virology353(2), 283–293 (2006).
  • Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo.J. Virol.74(20), 9451–9463 (2000).
  • Samulski Rj, Berns KI, Tan M, Muzyczka N. Cloning of infectious adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl Acad. Sci. USA79(6), 2077–2081 (1982).
  • Carter BJ. Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol. Ther.10(6), 981–989 (2004).
  • Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther.3(4), 281–304 (2003).
  • Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol.72(3), 2224–2232 (1998).
  • Merten O-W, Gény-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. Gene Ther.12(Suppl. 1), S51–S61 (2005).
  • Zolotukhin S. Production of recombinant adeno-associated virus vectors. Hum. Gene Ther.16(5), 551–557 (2005).
  • Le Bec C, Douar AM. Gene therapy progress and prospects – vectorology: design and production of expression cassettes in AAV vectors. Gene Ther.13(10), 805–813 (2006).
  • Zolotukhin S, Byrne BJ, Mason E et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther.6(6), 973–985 (1999).
  • Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther.14(1), 97–106 (2006).
  • Zhang HG, Xie J, Dmitriev I et al. Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production. J. Virol.76(23), 12023–12031 (2002).
  • During MJ, Samulski RJ, Elsworth JD et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther.5(6), 820–827 (1998).
  • Herzog RW. AAV-mediated gene transfer to skeletal muscle. Methods Mol. Biol.246, 179–194 (2004).
  • Snyder RO, Miao CH, Meuse L et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med.5(1), 64–70 (1999).
  • Zhong L, Zhao W, Wu J, Maina N, Han Z, Srivastava A. Adeno-associated virus-mediated gene transfer in hematopoietic stem/progenitor cells as a therapeutic tool. Curr. Gene Ther.6(6), 683–698 (2006).
  • Pacak CA, Mah CS, Thattaliyath BD et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo.Circ. Res.99(4), e3–e9 (2006).
  • Burger C, Gorbatyuk OS, Velardo MJ et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther.10(2), 302–317 (2004).
  • Davidson BL, Stein CS, Heth JA et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl Acad. Sci. USA97(7), 3428–3432 (2000).
  • Nakai H, Fues S, Storm S, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol.79(1), 214–224 (2005).
  • Wang Z, Zhu T, Qiao C et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol.23(3), 321–328 (2005).
  • Gregorevic P, Blankinship MJ, Allen JM et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med.10(8), 828–834 (2004).
  • Grimm D, Pandey K, Nakai H, Storm TA, Kay MA. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J. Virol.80(1), 426–439 (2006).
  • Gao GP, Alvira MR, Wang L et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA99(18), 11854–11859 (2002).
  • Blankinship MJ, Gregorevic P, Allen JM et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther.10(4), 671–678 (2004).
  • Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther.2(6), 619–623 (2000).
  • McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet.38, 819–845 (2004).
  • Huser D, Weger S, Heilbronn R. Kinetics and frequency of adeno-associated virus site-specific integration into human chromosome 19 monitored by quantitative real-time PCR. J. Virol.76(15), 7554–7559 (2002).
  • Nakai H, Montini E, Fuess S et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet.34(3), 297–302 (2003).
  • Nakai H, Wu X, Fuess S et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J. Virol.79(6), 3606–3614 (2005).
  • Nakai H, Yant SR, Storm T et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.J. Virol.75(15), 6969–6976 (2001).
  • Schnepp BC, Clark KR, Klemanski DL et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J. Virol.77(6), 3495–3504 (2003).
  • Flotte TR, Zeitlin PL, Reynolds TC et al. Phase I trial of of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther.14(11), 1079–1088 (2003).
  • Carter BJ. Adeno-associated virus vectors in clinical trials. Hum. Gene Ther.16(5), 541–550 (2005).
  • Warrington KH Jr, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet.119(6), 571–603 (2006).
  • Moss RB, Rodman D, Spencer LT et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multi-center, double-blind, placebo-controlled trial. Chest125(2), 509–521 (2004).
  • Manno CS, Chew AJ, Hutchison S et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood101(8), 2963–2972 (2003).
  • Jiang H, Pierce GF, Ozelo MC et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther.14(3), 452–455 (2006).
  • Manno CS, Pierce GF, Arruda VR et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med.12(3), 342–347 (2006).
  • Boyce N. Trial halted after gene shows up in semen. Nature414(6865), 677 (2001).
  • Ghazizadeh S, Taichman LB. Virus-mediated gene transfer for cutaneous gene therapy. Gene Ther.11(16), 2247–2251 (2000).
  • Meyers C, Mane M, Kokorina N et al. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology272(2), 338–346 (2000).
  • Hermonat PL, Plott RT, Santin AD et al. Adeno-associated virus Rep 78 inhibitis oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol. Oncol.66(3), 487–494 (1997).
  • Braun-Falco M, Doenecke A, Smola H, Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Ther.6(3), 432–441 (1999).
  • Braun-Falco M, Eisenried A, Büning H, Ring J. Recombinant adeno-associated virus-mediated gene transfer into human keratinocytes is influenced by both ubiquitin/proteasome pathway and epidermal growth factor-receptor tyrosine kinase. Arch. Dermatol. Res.296(11), 528–535 (2005).
  • Büning H, Braun-Falco M, Hallek M. Progress in the use of adeno-associated virus vectors for gene therapy. Cells Tiss. Org.177(3), 139–150 (2004).
  • Agrawal N, You H, Liu Y et al. Generation of recombinant skin in vitro by adeno-associated virus type 2 vector transduction. Tiss. Eng.10(11/12), 1707–1715 (2004).
  • Recchia A, Perani L, Sartori D et al. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther.10(4), 660–669 (2004).
  • Hengge UR, Mirmohammadsadegh A. Adeno-associated virus expresses transgenes in hair follicles and epidermis. Mol. Ther.2(3), 188–194 (2000).
  • Donahue BA, McArthur JG, Spratt SK et al. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J. Gene Med.1(1), 31–42 (1999).
  • Brigham PA, McLoughlin E. Burn incidence and medical care use in the United States: estimates, trends, and data sources. J. Burn Care Rehab.17(2), 95–107 (1996).
  • Martin P. Wound healing-aiming for perfect skin regeneration. Science276(5309), 75–81 (1997).
  • Branski LK, Pereira CT, Herndon DN, Jeschke MG. Gene therapy in wound healing: present status and future directions. Gene Ther.14(1), 1–10 (2007).
  • Deodato B, Arsic N, Zentilin L et al. Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Ther.9(12), 777–785 (2002).
  • Galeano M, Deodato B, Altavilla D et al. Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia46(4), 546–555 (2003).
  • Galeano M, Deodato B, Altavilla D et al. Effect of recombinant adeno-associated virus vector-mediated vascular endothelial growth factor gene transfer on wound healing after burn injury. Crit. Care Med.31(4), 1017–1025 (2003).
  • Uutela M, Wirzenius M, Paavonen K et al. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood104(10), 3198–3204 (2004).
  • Zacchigna S, Papa G, Antonini A et al. Improved survivial of ischemic cutaneous and musculocutaneous flaps after vascular endothelial growth factor gene transfer using adeno-associated virus vectors. Am. J. Pathol.167(4), 981–991 (2005).
  • Rivera VM, Gao G-P, Grant RL et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood105(4), 1424–1430 (2005).
  • Hengge UR. Gene therapy progress and prospects: the skin-easily accessible, but still far away. Gene Ther.13(22), 1555–1563 (2006).
  • Mavilio F, Pellegrini G, Ferrari S et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med.12(12), 1397–1402 (2006).
  • Duan D, Yue Y, Yan Z, Engelhardt JF. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med.6(5), 595–598 (2000).
  • Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med.6(5), 599–602 (2000).
  • Watt FM. Epidermal stem cells as targets for gene transfer. Hum. Gene Ther.11(16), 2261–2266 (2000).
  • Haug S, Braun-Falco M. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implication for gene therapy in Sjögren–Larsson syndrome. Arch. Dermatol. Res.296(12), 568–572 (2005).
  • Haug S, Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren–Larsson syndrome. Gene Ther.13(13) 1021–1026 (2006).
  • De Semir D, Aran JM. Targeted gene repair: the ups and downs of a promising gene therapy approach. Curr. Gene Ther.6(4), 481–504 (2006).
  • Xia H, Mao Q, Eliason SL et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med.10(8), 816–820 (2004).
  • Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp. Eye Res.84(1), 44–52 (2007).
  • Vasileva A, Jessberger R. Precise hit: adeno-associated virus in gene targeting. Nat. Rev. Microbiol.3(11), 837–847 (2005).
  • Chamberlain JR, Schwarze U, Wang P-R et al. Gene targeting in stem cells form individuals with osteogenesis imperfecta. Science303(5661), 1198–1201 (2004).
  • Cao H, Tsai SY, O’Malley BW, Wang X-J, Roop DR. The epidermis as a bioreactor: Topically regulated cutaneous delivery into the circulation. Hum. Gene Ther.13(9), 1075–1080 (2002).
  • Descamps V, Blumenfeld N, Beuzard Y, Perricaudet M. Keratinocytes as a target for gene therapy. Sustained production of erythropoietin in mice by human keratinocytes transduced with an adeno-associated virus vector. Arch. Dermatol.132(10), 1207–1211 (1996).
  • Hacker U, Wingenfeld L, Kofler DM et al. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J. Gene Med.7(11), 1429–1438 (2005).
  • Braun-Falco M, Hallek M. Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response. Arch. Dermatol. Res.293(1–2), 12–17 (2001).
  • Schoensiegel F, Paschen A, Sieger S et al. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther.11(6), 408–418 (2004).
  • Lin J, Lalani AS, Harding TC et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res.65(15), 6901–6909 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.